Lantern Pharma shares are trading higher after the company announced LP-184 received FDA fast-track designation status for Glioblastoma.
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma shares rose after the FDA granted fast-track designation to LP-184 for Glioblastoma treatment.
October 15, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma's stock is trading higher following the FDA's fast-track designation for its drug LP-184, aimed at treating Glioblastoma.
The FDA fast-track designation is a significant regulatory milestone that can expedite the development and review process of LP-184, potentially leading to faster market entry. This positive development is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100